PharmaShots Weekly Snapshots (May 08 - 12, 2023)

Share this

PharmaShots Weekly Snapshots (May 08 - 12, 2023)

Sanofi Reports P-IIIb Trial (HARMONIE) Results of Nirsevimab for the Prevention of Hospitalizations due to RSV-Related LRTD

Date: May 12, 2023 | Tags: Sanofi, Nirsevimab, RSV-Related LRTD, Clinical Trial, P-IIIb, HARMONIE Trial 

G1 Therapeutics Presents Preliminary Results from P-II Trial of Trilaciclib for Triple-Negative Breast Cancer at ESMO 2023

Date: May 12, 2023 | Tags: G1 Therapeutics, Trilaciclib, Triple-Negative Breast Cancer, Clinical Trial, P-II, Trial, ESMO 2023

Otsuka and Lundbeck Receive the US FDA’s Approval for Rexulti (brexpiprazole) sNDA to Treat Agitation Associated with Dementia Due to Alzheimer’s Disease

Date: May 12, 2023 | Tags: Otsuka, Lundbeck, Rexulti, brexpiprazole, Agitation, Dementia, Alzheimer’s DiseasesNDA Regulatory, US, FDA, Approval  

Cyclerion Therapeutics Sell Rights of Zagociguat and CY3018 to NewCo for the Treatment of Mitochondrial and Neurological Disease

Date: May 12, 2023 | Tags: Cyclerion Therapeutics, NewCo, Zagociguat, CY3018, Mitochondrial, Neurological Disease, Pharma

Jaguar Animal Health Reports an Availability of Canalevia-CA1 on Chewy for Chemotherapy-Induced Diarrhea in Dogs

Date: May 12, 2023 | Tags: Jaguar Animal Health, Canalevia-CA1, Chemotherapy-Induced Diarrhea, Dogs, Chewy, Animal Health

SERB Acquires US Rights from SFJ for Bentracimab

Date: May 12, 2023 | Tags: SERB, SFJ, Bentracimab, Brilinta, Ticagrelor, heart attack, stroke, acute coronary syndromes, coronary artery disease, Pharma, NEJM, US 

Angelini Pharma Collaborated with JCR Pharmaceuticals to Develop and Commercialize Novel Biologic Therapies for Epilepsy

Date: May 11, 2023 | Tags: Angelini Pharma, JCR Pharmaceuticals, Biologic, Epilepsy, J-Brain Cargo, Biotech

Bayer Entered into a Collaboration Agreement with Bicycle Therapeutics for the Development of Novel Targeted Radionuclide Therapies in Oncology

Date: May 11, 2023 | Tags: Bayer, Bicycle Therapeutics, Radionuclide Therapies, Oncology, peptide-based technology, Biotech

UCB Entered into a Research Collaboration with Ariceum Therapeutics to Discover New Modalities for Immune-related Diseases and Cancer

Date: May 11, 2023 | Tags: UCB, Ariceum Therapeutics, 177Lu-satoreotide tetraxetan, ExtremeDiversity, Immune-related Diseases, Cancer, biotech

AstraZeneca’s Ultomiris (ravulizumab) Receives EC’s Approval for the Treatment of Neuromyelitis Optica Spectrum Disorder in EU

Date: May 11, 2023 | Tags: AstraZeneca, Ultomiris, ravulizumab, Neuromyelitis Optica Spectrum Disorder, Regulatory, EU, Approval

Innovent Reports P-II Clinical Trial Results of Mazdutide (IBI362) for the Treatment of Obesity in Chinese Adults

Date: May 11, 2023 | Tags: Innovent, Mazdutide, IBI362, OXM3, Obesity, Clinical Trial, P-II Trial 

Servier’s Tibsovo (ivosidenib) Receives EC’s Approval for IDH1-Mutated Acute Myeloid Leukemia and IDH1-Mutated Cholangiocarcinoma

Date: May 11, 2023 | Tags: Servier, Tibsovo, ivosidenib, IDH1-Mutated, Acute Myeloid Leukemia, Cholangiocarcinoma, Regulatory, EC, Approval

Alvotech Entered into an Exclusive Agreement with Polifarma to Commercialize AVT06, a Proposed Biosimilar to Eylea (aflibercept) in Turkey

Date: May 10, 2023 | Tags: Alvotech, Polifarma, AVT06, Biosimilar, Eylea, aflibercept, neovascular, age-related macular degeneration, ophthalmology, Turkey, Pharma

Innovent and Eli Lilly Receive the NMPA’s Approval of Tyvyt (sintilimab) sNDA for EGFR-Mutated Non-Squamous NSCLC 

Date: May 10, 2023 | Tags: Innovent, Eli Lilly, Tyvyt, sintilimab, EGFR-mutated, Non-Squamous, NSCLC, Regulatory, NMPA, Approval, Lancet Respiratory Medicine 

Janssen Presents P-III Induction Study (QUASAR) Results of Tremfya (guselkumab) for Moderately to Severely Active Ulcerative Colitis at DDW 2023

Date: May 10, 2023 | Tags: Janssen, Tremfya, guselkumab, Ulcerative Colitis, DDW, 2023Clinical Trial, P-III, QUASAR Study 

Sobi to Acquire CTI BioPharma for ~$1.7B

Date: May 10, 2023 | Tags: Sobi, CTI BioPharma, Vonjo, hematology, ~$1.7B, M&A,

AstraZeneca’s Farxiga (dapagliflozin) Receives the US FDA’s Approval for the Treatment of Heart Failure

Date: May 10, 2023 | Tags: AstraZeneca, Farxiga, dapagliflozin, Heart Failure, Regulatory, US, FDA, Approval 

Amgen Entered into a Multi-Year Collaboration Agreement with Tscan Therapeutics to Identify Novel Targets for Crohn's Disease

Date: May 10, 2023 | Tags: Amgen, Tscan Therapeutics, Crohn's Disease, target discovery platform, Pharma

Amgen Reports Real-World Study Results of Prolia (denosumab) for Osteoporosis Associated with High Fracture Risk

Date: May 09, 2023 | Tags: Amgen, Prolia, denosumab, Osteoporosis, major osteoporotic, Real-World Study, Clinical Trial, WCO-IOF-ESCEO, 2023  

Sanofi and Regeneron Report P-III Trial (PRIME) and (PRIME2) Results of Dupixent (dupilumab) for the Treatment of Prurigo Nodularis

Date: May 09, 2023 | Tags: Sanofi, Regeneron, Dupixent, dupilumab, Prurigo Nodularis, Clinical Trial, P-III, PRIME, PRIME2 Trial 

Rhythm’s Imcivree (setmelanotide) Receives Health Canada Approval for Weight Management in Adult and Pediatric Patients with Obesity

Date: May 09, 2023 | Tags: Rhythm, Imcivree, setmelanotide, Obesity, Regulatory, Health Canada, Approval 

Genentech Reports the US FDA Acceptance of sBLA for Vabysmo to Treat Retinal Vein Occlusion

Date: May 09, 2023 | Tags: Genentech, Vabysmo, Retinal Vein Occlusion, sBLA, Regulatory, US, FDA, BALATON, COMINO Trial

Zion Pharma Signs an Agreement with Roche to Develop and Commercialize ZN-A-1041 for HER2-Positive Breast Cancer

Date: May 09, 2023 | Tags: Zion Pharma, Roche, ZN-A-1041, Breast Cancer, Pharma

Acorda Therapeutics Entered into a Distribution and Supply Agreement with Chance Pharmaceuticals to Commercialize Inbrija in China

Date: May 09, 2023 | Tags: Acorda Therapeutics, Chance Pharmaceuticals, Inbrija, China, Ampyra, dalfampridine, Pharma

Seres Therapeutics and Nestlé Health Science Present P-III Study (ECOSPOR IV) Results Vowst for Prevention of Recurrence of C. Difficile Infection at DDW 2023

Date: May 08, 2023 | Tags: Seres Therapeutics, Nestlé Health Science, Vowst, Recurrence of C. Difficile Infection, Clinical Trial, DDW 2023, P-III, ECOSPOR IV Study 

AstraZeneca’s Koselugo (selumetinib) Receives the NMPA’s Approval for the Treatment of Rare Genetic Disorder in Paediatric Patients

Date: May 08, 2023 | Tags: AstraZeneca, Koselugo, selumetinib, Neurofibromatosis Type 1, Plexiform Neurofibromas, Regulatory, NMPA, Approval  

Zoetis’ Librela (bedinvetmab) Receives the US FDA’s Approval to Control Osteoarthritis Pain in Dogs

Date: May 08, 2023 | Tags: Zoetis, Librela, bedinvetmab, Osteoarthritis Pain, Dogs, Regulatory, Animal Health, US, FDA, Approval 

Junshi Biosciences Collaborated with Dr. Reddy’s to Develop and Commercialize Toripalimab for the Treatment of Cancer

Date: May 08, 2023 | Tags: Junshi Biosciences, Dr. Reddy’s, Toripalimab, Cancer, Latin America, India, South Africa, biotech 

Innovent Reports P-III Study (ORIENT-31) Results of Sintilimab for EGFR-TKI Failed EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Date: May 08, 2023 | Tags: Innovent, Sintilimab, EGFR-TKI, EGFR-Mutated, Non-Squamous, Non-Small Cell Lung Cancer, Clinical Trial, P-III, ORIENT-31 Study, Lancet Respiratory Medicine

Bliss Biopharmaceutical Entered into a Clinical Trial Collaboration Agreement with Eisai for BB-1701 to Treat Cancers

Date: May 08, 2023 | Tags: Bliss Biopharmaceutical, Eisai, BB-1701, Cancers, solid tumors, Pharma

Related Post: PharmaShots Weekly Snapshots (May 01 - 05, 2023)

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions